News Releases
Azenta Life Sciences Reports Results of First Quarter of Fiscal 2022, Ended December 31, 2021
Continued Double-Digit Growth, Healthy End Markets, and a Strong Balance Sheet

CHELMSFORD, Mass., Feb. 8, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fiscal quarter ended December 31, 2021.

Summary of Results

Results of continuing operations reflect the Life Sciences business. Due to the agreement reached in the fourth fiscal quarter of 2021 to divest the semiconductor automation business, the results of the semiconductor automation business are treated as discontinued operations and reflected in total diluted EPS.

   

Quarter Ended

       

Dollars in millions, except per share data

 

December 31, 

 

September 30,

 

December 31, 

 

Change

 
   

2021

 

2021

 

2020

 

Prior Qtr.

 

Prior Yr.

 

Revenue from Continuing Operations

 

$

140

 

$

137

 

$

118

 

2

%

18

%

Life Sciences Products

 

$

50

 

$

53

 

$

46

 

(6)

%

10

%

Life Sciences Services

 

$

90

 

$

84

 

$

73

 

7

%

24

%

                             

Diluted EPS Continuing Operations

 

$

0.04

 

$

(0.30)

 

$

0.04

 

113

%

5

%

Diluted EPS Total

 

$

0.58

 

$

0.29

 

$

0.35

 

98

%

65

%

                             

Non-GAAP Diluted EPS Continuing Operations

 

$

0.12

 

$

0.12

 

$

0.13

 

1

%

(5)

%

Adjusted EBITDA Continuing Operations

 

$

20

 

$

21

 

$

22

 

(7)

%

(11)

%

Management Comments

"Fiscal 2022 started strong with continued robust demand for our product and service offerings," stated Steve Schwartz, President and CEO. "Azenta is winning and executing around the globe, while expanding and deepening customer relationships as a critical part of their end-to-end processes.  With the closing of the sale of the semiconductor business on February 1st, we are now a standalone life sciences company with a strong balance sheet to pursue strategic growth opportunities."

Summary of Q1 GAAP Results

  • Revenue from continuing operations for the first quarter was $140 million, up 18% year over year. Year-over-year organic growth was 16%.
  • Revenue from Life Sciences Products grew 10% year over year driven by strength in automated ultra-cold storage systems, and Life Sciences Services was up 24% with more than 20% growth in both Sample Repository Solutions and Genomic Services.
  • Operating loss for the first quarter was $0.3 million. Gross margin was 48.0% and operating expense of $67.4 million included approximately $3.7 million of professional fees in support of M&A initiatives.
  • We recorded a net benefit of $4.7 million from income tax, driven by the windfall tax benefit from stock compensation treatment recorded at time of vesting in the quarter. 
  • Diluted EPS from continuing operations was $0.04 per share, essentially flat compared to the first quarter of 2021. Total diluted EPS of $0.58 includes $0.54 of diluted EPS from discontinued operations.

Summary of Q1 Non-GAAP Earnings for Continuing Operations

 

The Continuing Operations view shown on a non-GAAP basis provides additional performance information by excluding the impact of M&A costs, amortization, restructuring, purchase price accounting, certain tax impacts, and special charges or gains, such as impairment losses. 

 

  • As referenced above, revenue in the first quarter was $140 million, up 18% year over year, with 10% growth in Life Sciences Products and 24% growth in Life Science Services.
  • Operating income was $12 million, up 7% year over year, and operating margin was 8.8%, down 90 basis points year over year and up 60 basis points sequentially. Gross margin of 49.3% was lower by 100 basis points year over year and 40 basis points sequentially. The gross margin of the Products business was 45.9%, up 20 basis points year over year and lower 200 basis points sequentially. The gross margin of the Services business was 51.2%, lower by 190 basis points year over year and up 40 basis points sequentially. Operating expense in the quarter was $56.6 million, lower by $0.2 million compared to Q4 2021, and up $8.7 million year over year. Operating expense in the quarter included approximately $3 million related to support from personnel which will roll off with the finalization of the sale.
  • Adjusted EBITDA was $20 million and Adjusted EBITDA margin was 14.2%, down 130 basis points from the fourth quarter of 2021.
  • Diluted EPS for the first quarter was $0.12, compared to $0.13 one year ago.

Cash and Liquidity

  • Cash flow from operations on a total company basis was $16 million for the quarter.
  • The Company ended the first fiscal quarter of 2022 with a total balance of cash, cash equivalents, restricted cash and marketable securities of $232 million which excludes $45 million of cash held in discontinued operations. Total debt was $50 million and net cash was $182 million.

Subsequent Event - Sale of the Semiconductor Automation Business  

As previously announced, the Company completed the sale of its semiconductor automation business on February 1, 2022 to Thomas H. Lee Partners for a cash price of $3.0 billion, subject to final working capital and other adjustments.  Net cash proceeds from the divestiture are expected to be approximately $2.4 billion upon the settlement of fees and taxes.  Upon closure of the sale on February 1, 2022, the Company utilized approximately $50 million of proceeds to extinguish outstanding debt.  The Company also terminated its revolving line of credit, which had no borrowings outstanding.

Guidance for Continuing Operations for Second Quarter Fiscal 2022

The Company announced revenue and earnings guidance for continuing operations for the second quarter of fiscal 2022.  Revenue is expected to be in the range of $137 million to $147 million and non-GAAP diluted earnings per share for the second fiscal quarter is expected to be in the range of $0.07 to $0.15.   GAAP diluted earnings per share from continuing operations is expected to be in the range of ($0.04) to $0.04

Conference Call and Webcast

Azenta management will webcast its first quarter earnings conference call today at 4:30 p.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events, and will be archived online on this website for convenient on-demand replay.  In addition, you may call 800-584-1012 (US & Canada only) or +1-212-231-2907 for international callers to listen to the live webcast.

Regulation G – Use of Non-GAAP financial Measures

The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers.  These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures.  A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets, statements of operations and statements of cash flows.

"Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. These forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to increase our profitability, our ability to improve or retain our market position, our ability to deliver financial success in the future, and our ability to invest the cash proceeds from the sale of our semiconductor automation business. Factors that could cause results to differ from our expectations include the following:  the impact of the COVID-19 global pandemic on the markets we serve, including our supply chain, and on the global economy generally, the volatility of the life sciences industries the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; the timing and effectiveness of cost reduction and cost control measures; price competition; disputes concerning intellectual property; uncertainties in global political and economic conditions, and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, current reports on Form 8-K and our quarterly reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

About Azenta Life Sciences

 

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. As of December 1st, the company changed its name and ticker to Azenta, Inc. (Nasdaq: AZTA) from Brooks Automation, Inc, (Nasdaq: BRKS).

 

Azenta is headquartered in Chelmsford, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

AZENTA INVESTOR CONTACTS:

Sara Silverman
Director of Investor Relations
Azenta Life Sciences
978.262.2635
sara.silverman@azenta.com

Sherry Dinsmore
Azenta Life Sciences
978.262.4301
sherry.dinsmore@azenta.com

AZENTA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)

(In thousands, except per share data)

 
 

Three Months Ended

 
 

December 31, 

 
 

2021

 

2020

 

Revenue

           

Products

$

45,869

 

$

41,462

 

Services

 

93,783

   

76,680

 

Total revenue

 

139,652

   

118,142

 

Cost of revenue

           

Products

 

24,523

   

22,793

 

Services

 

48,085

   

38,014

 

Total cost of revenue

 

72,608

   

60,807

 

Gross profit

 

67,044

   

57,335

 

Operating expenses

           

Research and development

 

6,485

   

5,088

 

Selling, general and administrative

 

60,711

   

51,930

 

Restructuring charges

 

173

   

(40)

 

Total operating expenses

 

67,369

   

56,979

 

Operating (loss) income

 

(325)

   

356

 

Interest income

 

35

   

76

 

Interest expense

 

(455)

   

(556)

 

Other income (expenses), net

 

(1,077)

   

1,281

 

(Loss) income before income taxes

 

(1,822)

   

1,156

 

Income tax benefit

 

(4,680)

   

(1,550)

 

Income from continuing operations

 

2,858

   

2,706

 

Income from discontinued operations, net of tax

 

40,462

   

23,322

 

Net income

$

43,320

 

$

26,028

 

Basic net income per share:

           

Income from continuing operations

$

0.04

 

$

0.04

 

Income from discontinued operations, net of tax

 

0.54

   

0.31

 

Basic net income per share

$

0.58

 

$

0.35

 

Diluted net income per share:

           

Income from continuing operations

$

0.04

 

$

0.04

 

Income from discontinued operations, net of tax

 

0.54

   

0.31

 

Diluted net income per share

$

0.58

 

$

0.35

 
             

Weighted average shares outstanding used in computing net income per share:

           

Basic

 

74,630

   

74,021

 

Diluted

 

74,866

   

74,283

 
             

 

AZENTA, INC.

CONSOLIDATED BALANCE SHEETS

(unaudited)

(In thousands, except share and per share data)

 
 

December 31, 

 

September 30,

 

2021

 

2021

           

Assets

         

Current assets

         

Cash and cash equivalents

$

215,168

 

$

227,427

Marketable securities

 

51

   

81

Accounts receivable, net

 

126,001

   

119,877

Inventories

 

70,143

   

60,398

Prepaid expenses and other current assets

 

60,833

   

58,198

Current assets held for sale

 

324,533

   

311,385

Total current assets

 

796,729

   

777,366

Property, plant and equipment, net

 

147,261

   

130,719

Long-term marketable securities

 

3,724

   

3,598

Long-term deferred tax assets

 

13,845

   

10,043

Goodwill

 

468,585

   

469,356

Intangible assets, net

 

178,589

   

186,534

Other assets

 

60,042

   

58,068

Non-current assets held for sale

 

186,162

   

183,828

Total assets

$

1,854,937

 

$

1,819,512

Liabilities and Stockholders' Equity

         

Current liabilities

         

Accounts payable

$

46,869

 

$

42,360

Deferred revenue

 

28,483

   

25,724

Accrued warranty and retrofit costs

 

2,342

   

2,330

Accrued compensation and benefits

 

24,872

   

33,183

Accrued restructuring costs

 

142

   

304

Accrued income taxes payable

 

14,037

   

8,711

Accrued expenses and other current liabilities

 

104,306

   

103,537

Current liabilities held for sale

 

120,749

   

128,939

Total current liabilities

 

341,800

   

345,088

Long-term debt

 

49,702

   

49,677

Long-term tax reserves

 

1,995

   

1,973

Long-term deferred tax liabilities

 

13,141

   

13,030

Long-term pension liabilities

 

726

   

705

Long-term operating lease liabilities

 

43,802

   

45,088

Other long-term liabilities

 

4,372

   

6,173

Non-current liabilities held for sale

 

31,976

   

32,444

Total liabilities

 

487,514

   

494,178

Commitments and contingencies

         

Stockholders' Equity

         

Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding

 

   

Common stock, $0.01 par value - 125,000,000 shares authorized, 88,375,410 shares issued and 74,913,541 shares outstanding at December 31, 2021, 87,808,922 shares issued and 74,347,053 shares outstanding at September 30, 2021

 

884

   

878

Additional paid-in capital

 

1,977,571

   

1,976,112

Accumulated other comprehensive income

 

24,149

   

19,351

Treasury stock at cost - 13,461,869 shares

 

(200,956)

   

(200,956)

Accumulated deficit

 

(434,225)

   

(470,051)

Total stockholders' equity

 

1,367,423

   

1,325,334

Total liabilities and stockholders' equity

$

1,854,937

 

$

1,819,512

 

AZENTA, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(In thousands)

 
   

Three Months Ended

   

December 31, 

   

2021

 

2020

Cash flows from operating activities

           

Net income

 

$

43,320

 

$

26,028

Adjustments to reconcile net income to net cash provided by operating activities:

           

Depreciation and amortization

   

12,883

   

15,746

Stock-based compensation

   

7,891

   

6,710

Amortization of premium on marketable securities and deferred financing costs

   

56

   

56

Deferred income taxes

   

(3,084)

   

(4,960)

Other gains on disposals of assets

   

(95)

   

1

Adjustment to the gain on divestiture, net of tax

   

   

948

Changes in operating assets and liabilities, net of acquisitions:

           

Accounts receivable

   

1,121

   

(4,504)

Inventories

   

(32,150)

   

(6,307)

Prepaid expenses and other assets

   

(19,647)

   

28,945

Accounts payable

   

(2,219)

   

5,727

Deferred revenue

   

4,056

   

3,186

Accrued warranty and retrofit costs

   

(103)

   

(185)

Accrued compensation and tax withholdings

   

(5,371)

   

(12,307)

Accrued restructuring costs

   

(154)

   

(75)

Accrued expenses and other liabilities

   

9,114

   

(15,279)

Net cash provided by operating activities

   

15,618

   

43,730

Cash flows from investing activities

           

Purchases of property, plant and equipment

   

(18,409)

   

(15,227)

Purchases of marketable securities

   

(46)

   

(4)

Sales of marketable securities

   

30

   

Acquisitions, net of cash acquired

   

   

(15,061)

Net cash used in investing activities

   

(18,425)

   

(30,292)

Cash flows from financing activities

           

Principal repayments of finance lease obligations

   

(186)

   

(319)

Principal payments on debt

   

   

(414)

Common stock dividends paid

   

(7,494)

   

(7,424)

Net cash used in financing activities

   

(7,680)

   

(8,157)

Effects of exchange rate changes on cash and cash equivalents

   

(1,804)

   

11,250

Net (decrease) increase in cash, cash equivalents and restricted cash

   

(12,291)

   

16,531

Cash, cash equivalents and restricted cash, beginning of period

   

285,333

   

302,526

Cash and cash equivalents and restricted cash, end of period

 

$

273,042

 

$

319,057

             

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets

           

Cash and cash equivalents of continuing operations

   

215,168

   

263,517

Cash and cash equivalents included in assets held for sale

   

45,000

   

45,000

Short-term restricted cash included in prepaid expenses and other current assets

   

3,568

   

3,571

Long-term restricted cash included in other assets

   

9,306

   

6,969

Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows

 

$

273,042

 

$

319,057

             

Notes on Non-GAAP Financial Measures

Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers.  Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.

                                     
   

Quarter Ended

   

December 31, 2021

 

September 30, 2021

 

December 31, 2020

       

per diluted

     

per diluted

     

per diluted

Dollars in thousands, except per share data    

 

$

 

share

 

$

 

share

 

$

 

share

Net income (loss) from continuing operations

 

$

2,858

 

$

0.04

 

$

(22,397)

 

$

(0.30)

 

$

2,706

 

$

0.04

Adjustments:

                                   

Amortization of intangible assets

   

8,046

   

0.11

   

9,515

   

0.13

   

8,910

   

0.12

Impairment of intangible assets

   

   

   

13,364

   

0.18

   

   

Restructuring charges

   

173

   

0.00

   

332

   

0.00

   

(40)

   

(0.00)

Merger and acquisition costs

   

3,719

   

0.05

   

8,427

   

0.11

   

2,191

   

0.03

Rebranding and transformation costs

   

619

   

0.01

   

827

   

0.01

   

   

Indemnification asset release

   

   

   

16,007

   

0.21

   

   

Tax adjustments (1)

   

(4,240)

   

(0.06)

   

(10,345)

   

(0.14)

   

(2,264)

   

(0.03)

Tax effect of adjustments 

   

(2,265)

   

(0.03)

   

(6,967)

   

(0.09)

   

(2,212)

   

(0.03)

Non-GAAP adjusted net income from continuing operations

 

$

8,910

 

$

0.12

 

$

8,763

 

$

0.12

 

$

9,292

 

$

0.13

   Stock based compensation, pre-tax

   

3,458

   

0.05

   

5,138

   

0.07

   

4,835

   

0.07

   Tax rate

   

15

%

 

   

15

%

 

   

15

%

 

Stock-based compensation, net of tax

   

2,939

   

0.04

   

4,367

   

0.06

   

4,110

   

0.06

Non-GAAP adjusted net income excluding stock-based compensation - continuing operations

 

$

11,850

 

$

0.16

 

$

13,130

 

$

0.18

 

$

13,401

 

$

0.18

                                     

Shares used in computing non-GAAP diluted net income per share

   

   

74,866

   

   

74,532

   

   

74,283

   

1)

Tax adjustments during the quarter ended December 31, 2021 and 2020, exclude tax benefits related to stock compensation windfalls. These benefits are recognized in the period of vesting for US GAAP but included in the annual effective tax rate for Non-GAAP reporting.  We have excluded $16.6 million of tax benefits during the quarter ended September 30, 2021 related to tax reserve reversals due to the expiration of statute of limitations on a liability primarily related to the GENEWIZ acquisition; and $1.5 million related to the timing differences in recognizing the tax benefit related to stock compensation windfall tax deductions. This is partially offset by the exclusion of a $3.4 million charge for the write-down of the tax basis of assets relating to the reversal of the GENEWIZ tax liability and the exclusion of $4.1 million of withholding tax costs associated with foreign cash repatriation. 

 

                     
   

Quarter Ended

 
   

December 31, 

 

September

 

December 31, 

 

Dollars in thousands

 

2021

 

2021

 

2020

 

GAAP net income

 

$

43,320

 

$

21,804

 

$

26,028

 

Adjustments:

                   

Less: Income from discontinued operations

   

(40,462)

   

(44,201)

   

(23,322)

 

Less: Interest income

   

(35)

   

(129)

   

(76)

 

Add: Interest expense

   

455

   

552

   

556

 

Add: Income tax benefit

   

(4,680)

   

(15,480)

   

(1,550)

 

Add: Depreciation

   

5,208

   

5,055

   

4,817

 

Add: Amortization of completed technology

   

1,773

   

1,873

   

2,005

 

Add: Amortization of customer relationships and acquired intangible assets

   

6,272

   

7,642

   

6,905

 

Earnings (loss) before interest, taxes, depreciation and amortization

 

$

11,851

 

$

(22,884)

 

$

15,364

 
                     
   

Quarter Ended

 
   

December 31, 

 

September

 

December 31, 

 

Dollars in thousands

 

2021

 

2021

 

2020

 

Earnings (loss) before interest, taxes, depreciation and amortization

 

$

11,851

 

$

(22,884)

 

$

15,364

 

Adjustments:

                   

Add: Stock-based compensation

   

3,458

   

5,138

   

4,835

 

Add: Restructuring charges

   

173

   

332

   

(40)

 

Add: Merger and acquisition costs

   

3,719

   

8,427

   

2,191

 

Impairment of intangible assets

   

   

13,364

   

 

Rebranding and transformation costs

   

619

   

827

   

 

Indemnification asset release

   

   

16,007

   

 

Adjusted earnings before interest, taxes, depreciation and amortization - Continuing operations

 

$

19,820

 

$

21,211

 

$

22,350

 

 

                                     
   

Quarter Ended

 

Dollars in thousands

 

December 31, 2021

 

September 30, 2021

 

December 31, 2020

GAAP gross profit

 

$

67,044

 

48.0

%

 

$

66,142

 

48.3

%

 

$

57,335

 

48.5

%

Adjustments:

                                   

Amortization of completed technology

   

1,773

 

1.3

     

1,873

 

1.4

     

2,005

 

1.7

 

Non-GAAP adjusted gross profit

 

$

68,817

 

49.3

%

 

$

68,015

 

49.7

%

 

$

59,340

 

50.2

%

                                     

 

                                                                         
   

 Life Sciences Products

 

Life Sciences Services

   

Quarter Ended

 

Quarter Ended

Dollars in thousands

 

December 31, 2021

 

September 30, 2021

 

December 31, 2020

 

December 31, 2021

 

September 30, 2021

 

December 31, 2020

GAAP gross profit

 

$

22,690

 

45.5

%

 

$

25,329

 

47.7

%

 

$

20,531

 

45.1

%

 

$

44,354

 

49.4

%

 

$

40,815

 

48.7

%

 

$

36,810

 

50.7

%

Adjustments:

                                                                       

Amortization of completed technology

   

203

 

0.4

     

132

 

0.2

     

273

 

0.6

     

1,570

 

1.7

     

1,741

 

2.1

     

1,732

 

2.4

 

Non-GAAP adjusted gross profit

 

$

22,894

 

45.9

%

 

$

25,461

 

47.9

%

 

$

20,804

 

45.7

%

 

$

45,924

 

51.2

%

 

$

42,556

 

50.8

%

 

$

38,542

 

53.1

%

                                                                         

 

                                     
   

 Life Sciences Products

 

Life Sciences Services

   

Quarter Ended

 

Quarter Ended

   

December 31, 

 

September

 

December 31, 

 

December 31, 

 

September

 

December 31, 

Dollars in thousands

 

2021

 

2021

 

2020

 

2021

 

2021

 

2020

GAAP operating profit

 

$

4,187

 

$

6,470

 

$

3,911

 

$

6,314

 

$

2,602

 

$

5,196

Adjustments:

                                   

Amortization of completed technology

   

203

   

132

   

273

   

1,570

   

1,741

   

1,732

Non-GAAP adjusted operating profit

 

$

4,390

 

$

6,602

 

$

4,184

 

$

7,884

 

$

4,343

 

$

6,928

 

                                                       
   

Total Segments

 

Corporate

 

Total

   

Quarter Ended

 

Quarter Ended

 

Quarter Ended

   

December 31, 

 

September

 

December 31, 

 

December 31, 

 

September

 

December 31, 

 

December 31, 

 

September

 

December 31, 

Dollars in thousands

 

2021

 

2021

 

2020

 

2021

 

2021

 

2020

 

2021

 

2021

 

2020

GAAP operating profit (loss)

 

$

10,501

 

$

9,072

 

$

9,107

 

$

(10,826)

 

$

(30,314)

 

$

(8,751)

 

$

(325)

 

$

(21,242)

 

$

356

Adjustments:

                                                     

Amortization of completed technology

   

1,773

   

1,873

   

2,005

   

   

   

   

1,773

   

1,873

   

2,005

Amortization of customer relationships and acquired intangible assets

   

   

   

   

6,272

   

7,642

   

6,905

   

6,272

   

7,642

   

6,905

Restructuring charges

   

   

   

   

173

   

332

   

(40)

   

173

   

332

   

(40)

Impairment of intangible assets

   

   

   

   

   

13,364

   

   

   

13,364

   

Rebranding and transformation costs

   

   

   

   

619

   

827

   

   

619

   

827

   

Merger and acquisition costs

   

   

   

   

3,719

   

8,427

   

2,191

   

3,719

   

8,427

   

2,191

Non-GAAP adjusted operating profit (loss)

 

$

12,274

 

$

10,945

 

$

11,112

 

$

(43)

 

$

278

 

$

305

 

$

12,231

 

$

11,223

 

$

11,417

Business Line Realignment – Life Sciences Services

In the third quarter of fiscal year 2020, as the Company integrated the Genomic Services component and the Sample Repository Solutions component to form the Life Sciences Services segment, the Company realigned certain laboratory services which existed in each business line to be managed underneath the Genomic Services business unit.  The table below reflects the revenue for our Sample Repository Solutions and Genomic Services businesses after the reclassification of these laboratory services over the historical quarterly periods and for the full fiscal years of 2021 and 2020. 

Management's discussion and analysis of results throughout fiscal year 2021 have previously reflected the revenue amounts reported below.  This table serves to update an immaterial misclassification in the disaggregated revenue disclosure in its Revenue from Contracts with Customers footnote in the Form 10-K for the fiscal year ended September 30, 2021, as well as to retroactively reclassify the footnote information for the quarterly periods and full fiscal year of 2020 for this business realignment to provide additional clarity.

                                 
   

Three Months Ended

 

Year Ended

 
     

December 31, 2020

   

March 31, 2021

   

June 30, 2021

   

September 30, 2021

 

September 30, 2021

 

Sample Repository Solutions

 

$

20,533

 

$

22,191

 

$

21,772

 

$

24,426

 

$

88,922

 

Genomic Services

   

52,101

   

54,989

   

58,690

   

59,398

   

225,176

 

Life Sciences Services

 

$

72,634

 

$

77,180

 

$

80,462

 

$

83,824

 

$

314,097

 
                                 
                                 
   

Three Months Ended

 

Year Ended

 
     

December 31, 2019

   

March 31, 2020

   

June 30, 2020

   

September 30, 2020

 

September 30, 2020

 

Sample Repository Solutions

 

$

21,232

 

$

22,292

 

$

25,279

 

$

21,045

 

$

89,847

 

Genomic Services

   

40,733

   

42,019

   

37,599

   

48,584

   

168,931

 

Life Sciences Services

 

$

61,964

 

$

64,311

 

$

62,877

 

$

69,628

 

$

258,778

 
                                 

 

(PRNewsfoto/Brooks Automation)

 

 

SOURCE Azenta

©2022 Azenta, Inc. All rights reserved. | Privacy & Security Policy
Loading data...